# Phase 1 obesity trials recruiting: 123 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 123 trials in phase 1 for obesity that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 obesity trials: 123 rows for $6.15, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 12 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/obesity

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 123
- Recruiting or not yet: 123
- Read on: November 19, 2026

## Trials

The 25 newest of 123, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944118 | Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in... | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Overweight, Obesity, Type 2 Diabetes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944118) |
| November 17, 2026 | NCT07940582 | A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or Obesity | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Overweight, Obesity | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940582) |
| November 16, 2026 | NCT07940244 | A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity | Boehringer Ingelheim | Phase 1 | Not yet recruiting | Healthy, Obesity | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940244) |
| November 16, 2026 | NCT07938515 | Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal... | Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 1 | Recruiting | Obesity & Overweight | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938515) |
| November 16, 2026 | NCT07937787 | A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With... | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Not yet recruiting | Overweight and Obesity, MASH - Metabolic Dysfunction-Associated Steatohepatitis | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937787) |
| November 13, 2026 | NCT07936058 | A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet | Hangzhou Sciwind Biosciences Co., Ltd. | Phase 1 | Not yet recruiting | Food Effect in Healthy Volunteers, Weight Management | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936058) |
| November 13, 2026 | NCT07935291 | Study of IPG1094 Tablets in Chinese Healthy Adults and Obese Adults | Nanjing Immunophage Biotech Co., Ltd | Phase 1 | Not yet recruiting | Healthy Volunteers; Obesity | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935291) |
| November 9, 2026 | NCT07924761 | A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living... | Kailera | Phase 1 | Not yet recruiting | Overweight or Obesity | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924761) |
| November 6, 2026 | NCT07922798 | A Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy Participants | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Not yet recruiting | Overweight , Obesity | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922798) |
| November 6, 2026 | NCT07921316 | Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous... | Amgen | Phase 1 | Not yet recruiting | Obesity, Overweight | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921316) |
| November 4, 2026 | NCT07916194 | A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Participants | Beijing QL Biopharmaceutical Co.,Ltd | Phase 1 | Not yet recruiting | Overweight, Obesity | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916194) |
| November 4, 2026 | NCT07915986 | Brain Dopamine Dynamics in Obesity | Yale University | Phase 1 | Not yet recruiting | Obesity | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915986) |
| November 4, 2026 | NCT07915245 | A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915245) |
| November 2, 2026 | NCT07911514 | A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 | AstraZeneca | Phase 1 | Not yet recruiting | Healthy Participants | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911514) |
| November 2, 2026 | NCT07908316 | Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After... | Amgen | Phase 1 | Recruiting | Obesity, Overweight | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908316) |
| October 23, 2026 | NCT07893106 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants... | Ascletis Pharma (China) Co., Limited | Phase 1 | Recruiting | Chronic Weight Management | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893106) |
| October 23, 2026 | NCT07893093 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants... | Ascletis Pharma (China) Co., Limited | Phase 1 | Recruiting | Chronic Weight Management | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893093) |
| October 22, 2026 | NCT07890870 | A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity. | iBio, Inc. | Phase 1 | Not yet recruiting | Obesity & Overweight | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890870) |
| October 20, 2026 | NCT07881887 | A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 617 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881887) |
| October 15, 2026 | NCT07877038 | Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function | Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 1 | Not yet recruiting | Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877038) |
| October 15, 2026 | NCT07876531 | A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or... | Pfizer | Phase 1 | Recruiting | Overweight and/or Obesity, Healthy Participants | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876531) |
| October 15, 2026 | NCT07876518 | A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity | Pfizer | Phase 1 | Not yet recruiting | Overweight and/or Obesity | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876518) |
| October 14, 2026 | NCT07873645 | Study of UBT37034 Injection | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Recruiting | Overweight , Obesity | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873645) |
| October 9, 2026 | NCT07868354 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868354) |
| October 2, 2026 | NCT07855133 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855133) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 24 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 8 |
| [Shanghai Minwei Biotechnology Co., Ltd](https://specstream.ai/data/clinical-trials/company/shanghai-minwei-biotechnology-co-ltd) | 5 |
| Columbia University | 4 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| The United Bio-Technology (Hengqin) Co., Ltd. | 3 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 3 |
| [Fujian Shengdi Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/fujian-shengdi-pharmaceutical-co-ltd) | 3 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 3 |
| Biolexis Therapeutics | 2 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 2 |
| Kailera | 2 |
| Chendu DIAO Pharmaceutical Group CO., LTD. | 2 |
| University of Colorado, Denver | 2 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 2 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 2 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 2 |
| Ascletis Pharma (China) Co., Limited | 2 |
| iBio, Inc. | 2 |
| Yale University | 2 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 2 |
| Verdiva Bio Dev Limited | 1 |
| [Gan & Lee Pharmaceuticals.](https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals) | 1 |
| Beijing QL Biopharmaceutical Co.,Ltd | 1 |
| MBX Biosciences | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 47 |
| China | 29 |
| Australia | 14 |
| Germany | 8 |
| Canada | 4 |
| Singapore | 4 |
| Denmark | 3 |
| Netherlands | 3 |
| United Kingdom | 3 |
| Japan | 1 |
| Sweden | 1 |
| Slovakia | 1 |
| South Korea | 1 |
| France | 1 |
| Austria | 1 |
| Portugal | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Architectural design firms in the United States](https://specstream.ai/data/businesses/architectural-design-firms/united-states)
- [Internal medicine practices in the United States](https://specstream.ai/data/businesses/internal-medicine-practices/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [High schools in the United States](https://specstream.ai/data/businesses/high-schools/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
- [Food and beverage distributors in the United States](https://specstream.ai/data/businesses/food-and-beverage-distributors/united-states)
